Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

The partnership builds on the success of Verastem’s Phase 2 RAMP-201 clinical trial, which led to the U.S. Food and Drug Administration’s accelerated approval of a combination therapy for KRAS ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data to be presented at the 2025 American Society of ...

Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of ...

Pachter, and Sanjib Chowdhury at Verastem (Needham, MA). Three additional applications from Verastem and Boundless Bio (San Diego) followed in 2023–2025. ORIC-114 is being developed by Oric ...

Other drugs in the class – Gilead Sciences' Zydelig (idelalisib), Bayer's Aliqopa (copanlisib) and Verastem's Copiktra (duvelisib) – have been approved for blood cancers like leukaemia and ...

Healthcare & Pharmaceuticalscategory· May 8, 2025 US FDA approves Verastem's ovarian cancer therapy The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients ...